Skip to main content

Table 1 Summary of the results of NASBA-OC testing of different clinical samples.

From: Simplified molecular detection of Leishmania parasites in various clinical samples from patients with leishmaniasis

Clinical Sample Number of Samples NASBA-OC positive Number of Samples NASBA-OC negative
Blood samples healthy controls from Sudan (n = 50) 0 50
Blood samples confirmed VL cases from Sudan (n = 30) 28 2
Skin biopsies of patients with other skin diseases from The Netherlands (n = 5) 0 5
Skin biopsies of patients with confirmed CL from Suriname (n = 27) 27 0
Skin biopsies of patients with confirmed CL from Brazil (n = 43) 42 1
Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) estimated at a 95% confidence interval (95% CI) of the NASBA-OC on different clinical samples
NASBA-OC employed on blood samples
Sensitivity 93.3% (95% CI: 76.5% - 98.8%)
Specificity 100% (95 CI: 91.1% - 100%)
PPV 100% (95% CI: 85.0 - 100%)
NPV 96.2% (95 CI: 85.7% - 99.3%)
NASBA-OC employed on skin biopsies
Sensitivity 98.6% (95% CI: 91.2% - 99.9%)
Specificity 100% (95% CI: 46.3% - 100%)
PPV 100% (95% CI: 93.4% - 100%)
NPV 83.3% (95% CI: 36.5% - 99.1%)